GE Healthcare and Lantheus Phase III Clinical Trial Finds [ 18 F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
GE Healthcare and Lantheus Holdings Inc (NASDAQ: LNTH) have announced that the recent Phase III clinical trial of their investigational radiotracer, [18F]flurpiridaz, has met its co-primary endpoints of exceeding a 60 percent threshold for both sensitivity and specificity for detecting Coronary Artery Disease (CAD). The findings, shared at the American Society of Nuclear Cardiology (ASNC) Congress, in Florida, U.S., also demonstrate [18F]flurpiridaz Positron Emission Tomography (PET) has higher diagnostic efficacy and image quality in patients with suspected CAD, compared with Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI), the predominant procedure used in nuclear cardiology today. SPECT MPI represents approximately 6 million procedures per year in the U.Si.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005138/en/
The Phase III Open-Label Study, which involved over 600 patients across sites in the U.S., Europe and Canada assessed the diagnostic efficacy of [18F]flurpiridaz in detecting CAD, the most common form of heart diseaseii and the leading cause of death globallyiii, with invasive coronary angiography as a standard of truth. More than 120 million people are affected by CAD globally each yeariv and in the U.S. alone, approximately 20 million adults have CAD, with nearly 383,000 deaths recorded in 2020v.
If approved, this investigational agent would offer the advantages of 18F, with broad available distribution and a half-life of almost two hours, removing the need for it to be manufactured in the immediate vicinity of the imaging department. This longer half-life could also make Flurpiridaz (18F) Injection suitable for exercise stress testing, which is not feasible with existing cardiac PET radiotracers.
Dr. Tim Bateman, MD, FACC, co-director of the Cardiovascular Radiologic Imaging Program at Saint Luke's Hospital, Missouri, US, shared: “These results are truly promising for the nuclear cardiology community and CAD patients. From ASNC’s inception, its leaders have laid out the specifications for an ideal myocardial perfusion tracer. In my view [18F]flurpiridaz could meet this goal, expanding how PET MPI can be used to image CAD patients moving forward.”
Dr. Francois Tranquart, MD, PhD, Global Head of Clinical Development for GE Healthcare Pharmaceutical Diagnostics, Research and Development, said: “The positive Phase III trial results are a key step towards future approval of Flurpiridaz (18F) Injection as a potential new cardiac PET agent which could improve the detection of coronary artery disease. This is another example of GE Healthcare investing in our portfolio of Molecular Imaging products to help improve diagnostic accuracy and patient outcomes.”
GE Healthcare has led the funding and development of [18F]flurpiridaz, and, if the imaging agent is approved, will have global commercialization rights. Lantheus has collaborated on the development and will also collaborate on potential commercialization through a joint steering committee. Lantheus is entitled to royalties based on commercial sales.
GE Healthcare’s Pharmaceutical Diagnostics unit is a global leader in imaging agents used to support around 100 million procedures per year globally, equivalent to three patients every second. Its Molecular Imaging portfolio combines an innovative pipeline with established proprietary products across cardiology, neurology and oncology.
About GE Healthcare:
GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 48,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.
With more than 60 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease. Lantheus is headquartered in Massachusetts and has offices in New Jersey, Canada and Sweden. For more information, visit www.lantheus.com.
i Data on File: AMR Market Guide 2021.
iiWHO Factsheet 2020. Cardiovascular diseases (CVDs). 11 June 2021.
v Centers for Disease Control and Prevention. Heart Disease Facts. Accessed July 15 2022.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
GEHealthcare Media Contact:
+44 7785 456999
Vice President, Investor Relations
Senior Director, Corporate Communications
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Opera Crypto Browser to unlock instant NFT publishing with Alteon LaunchPad5.12.2022 18:16:00 CET | Press release
Opera Crypto Browser, the world’s first multi-platform Web3 browser, is about to give millions of users the power to easily upload media to a blockchain and create NFTs, thanks to a new partnership with Alteon.io, an all-in-one ecosystem for content creators whose mission is to democratize the creative process. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221205005557/en/ Alteon LaunchPad, coming soon exclusively to Opera Crypto Browser, will allow anyone to mint an NFT in real-time. (Photo: Business Wire) With Alteon LaunchPad, users who have little to no experience in Web3 or NFTs will be able to drag and drop any media file into the browser, which will automatically write a simple smart contract and upload the file to a blockchain—transforming NFTs into an accessible media type for all to explore and enjoy. This unprecedented tool, the first of its kind for any type of browser, democratizes NFTs, empowering artists of a
Saudi Space Commission announces launch of Saudi Space Accelerator Program5.12.2022 15:52:00 CET | Press release
Saudi Space Commission announces the launch of its Saudi Space Accelerator Program in line with the Kingdom's vision of becoming a global hub of innovation by 2030. The program seeks to enhance the national Space sector through the development of its infrastructure and enabling local entrepreneurs and businesses to advance innovative Space solutions. The Program addresses the current state in the Kingdom's Space sector and proposes proactive Space solutions. Through the implementation of this program, the commission will ignite the local ecosystem and determine its maturity level, and to ensure that the sector remains viable for years to come, by providing an established business environment for growth and innovation for entrepreneurs to thrive in – overall improving the effectiveness of the commission's future programs and initiatives over the long-run. The Saudi Space Accelerator Program is being supported by a greater initiative; The future Office for Entrepreneurship Development, t
Advent Technologies Completes Fuel Cell Project for the European Space Agency5.12.2022 15:00:00 CET | Press release
Advent Technologies Holdings, Inc. (NASDAQ: ADN) (“Advent“ or the “Company”), an innovation-driven leader in the fuel cell and hydrogen technology space, today announced the successful completion of a research and development project commissioned under a programme of and funded by the European Space Agency (“ESA”), dedicated to the development of a closed-loop regenerative fuel cell system (“RFCS”) earlier this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221205005299/en/ The project started in 2014, with Advent as the prime contractor. Subcontractors included the Centre for Research and Technology – Hellas, the Foundation for Research and Technology – Hellas, and the University of Patras. The project concluded with the successful delivery of the high-temperature proton exchange membrane (“HT-PEM”) stack to ESA. During a highly successful testing phase, the RFCS demonstrated its ability to effectively meet the power
Duravant Acquires Marelec Food Technologies5.12.2022 15:00:00 CET | Press release
Duravant LLC (“Duravant”), a global engineered equipment and automation solutions provider to the food processing, packaging and material handling sectors, announced today that it has acquired Marelec Food Technologies (“Marelec”), a leading manufacturer of intelligent portioning and customized weighing and grading solutions headquartered in Nieuwpoort, Belgium. Marelec serves the poultry, meat, seafood and marine sectors, designing and manufacturing innovative turnkey systems that ensure high-quality output and maximum yield for food processors around the world. “Our new partnership further enhances Duravant’s front line position in the growing food processing segment,” said Mike Kachmer, President and CEO of Duravant. “Marelec’s intense focus on providing outstanding service and continuous innovation has been the foundation of their success, and their legacy of market leadership makes them a perfect addition to the Duravant family.” Recognized globally as a high-tech solutions provid
First Patients in the World Treated with Impella RP Flex with SmartAssist5.12.2022 14:03:00 CET | Press release
Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have already returned home with their native heart. The patients were treated at Hackensack University Medical Center/Hackensack Meridian Health in Hackensack, N.J., and Kingwood Medical Center in Kingwood, Texas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221205005137/en/ Impella RP Flex with SmartAssist Illustration (Graphic: Business Wire) Impella RP Flex is implanted percutaneously through the internal jugular (IJ) vein, which provides the option for patient mobility while on support, and is designed to be easy to implant, with a flexible canula that is advanced over an extra-supportive guidewire. It includes SmartAssist dual-sensor techn